Our core facility is phasing out our 454 and the same is happening at our collaborator's institution. Is this a general trend and if so, is there still interest in the development of tools to analyze 454 data?
Seqanswers Leaderboard Ad
Collapse
Announcement
Collapse
No announcement yet.
X
-
We have no immediate plans to phase it out but our 454 service has slowed to a trickle. We have not received our FLX+ upgrade yet and frankly I doubt it will have any impact on usage. It seems to me that 454 has completely lost mind share within the community and, it appears, within Roche itself.
-
454 sequencing is still in demand here (Norway). Last year we had many more amplicon than shotgun projects. Now, shotgun is picking up again, perhaps due to FLX+. But, it took a long time (>6 months!) before our upgraded instrument worked again, so we are only now beginning to test FLX+ sequencing. We are getting longer and longer reads, but not yet with the peak (mode) length around 750-800 bases.
Comment
-
We've just inherited a 454 Junior (we're a molecular pathology diagnostic lab with a dedicated R&D team) and we've been invited to participate in a multi-centre trial (amplicon deep seq), all based around 454. However, it seems to us (without being very familiar with the platform) that the relatively low-throughput/high run cost, when compared to the IonTorrent & MiSeq, make it seem like the third-choice platform to conduct the trial on - are we correct in this assumption or is there still life in the old dog yet?
Additionally, can anyone give us an up-to-date throughput/cost estimate? (we're going by 10MB / £1000).
Comment
-
Originally posted by tyfach View PostWe've just inherited a 454 Junior (we're a molecular pathology diagnostic lab with a dedicated R&D team) and we've been invited to participate in a multi-centre trial (amplicon deep seq), all based around 454. However, it seems to us (without being very familiar with the platform) that the relatively low-throughput/high run cost, when compared to the IonTorrent & MiSeq, make it seem like the third-choice platform to conduct the trial on - are we correct in this assumption or is there still life in the old dog yet?
Additionally, can anyone give us an up-to-date throughput/cost estimate? (we're going by 10MB / £1000).
Comment
Latest Articles
Collapse
-
by seqadmin
The field of epigenetics has traditionally concentrated more on DNA and how changes like methylation and phosphorylation of histones impact gene expression and regulation. However, our increased understanding of RNA modifications and their importance in cellular processes has led to a rise in epitranscriptomics research. “Epitranscriptomics brings together the concepts of epigenetics and gene expression,” explained Adrien Leger, PhD, Principal Research Scientist...-
Channel: Articles
04-22-2024, 07:01 AM -
-
by seqadmin
Proteins are often described as the workhorses of the cell, and identifying their sequences is key to understanding their role in biological processes and disease. Currently, the most common technique used to determine protein sequences is mass spectrometry. While still a valuable tool, mass spectrometry faces several limitations and requires a highly experienced scientist familiar with the equipment to operate it. Additionally, other proteomic methods, like affinity assays, are constrained...-
Channel: Articles
04-04-2024, 04:25 PM -
ad_right_rmr
Collapse
News
Collapse
Topics | Statistics | Last Post | ||
---|---|---|---|---|
Started by seqadmin, Today, 08:47 AM
|
0 responses
11 views
0 likes
|
Last Post
by seqadmin
Today, 08:47 AM
|
||
Started by seqadmin, 04-11-2024, 12:08 PM
|
0 responses
60 views
0 likes
|
Last Post
by seqadmin
04-11-2024, 12:08 PM
|
||
Started by seqadmin, 04-10-2024, 10:19 PM
|
0 responses
59 views
0 likes
|
Last Post
by seqadmin
04-10-2024, 10:19 PM
|
||
Started by seqadmin, 04-10-2024, 09:21 AM
|
0 responses
54 views
0 likes
|
Last Post
by seqadmin
04-10-2024, 09:21 AM
|
Comment